Sign in
WithdrawnNo phase

Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
Sept 2025
Expected to end
31 Dec 2027
Type of study
Observational
Treatments tested
  • Computed tomography coronary angiogram
Record updated
6 March 2025
Why it stopped
Insufficient funding

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • All consecutive patients on record who underwent coronary artery bypass graft surgery in 2007 and 2008

Who cannot take part

  • Concomitant valve and aortic procedures
  • Concomitant repair of post-infarct ventricular septal rupture
  • Intermediate to high risk for contrast nephropathy, defined as estimated glomerular filtration rate less than 45 ml/min/1.73m2 or serum creatinine level <1.5 mg/dL (based on American College of Radiology criteria for diagnostic computed tomography risk)
  • Death
  • Single vessel LIMA-LAD anastomosis only
  • Defaulted follow-up
  • Informed consent cannot be obtained
  • Pregnancy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This single-centre cross-sectional study aims to ascertain the impact of dyslipidemia on long-term graft patency after coronary artery bypass grafting (CABG).

Treatments tested

  • Computed tomography coronary angiogram

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Cholesterol Level on Long-term Angiographic Outcome of Coronary Artery Bypass Grafting
Record updated
6 March 2025